Immunocore Holdings plc
IMCR
$28.38
-$1.67-5.54%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 24.37% | 24.32% | 26.54% | 31.02% | 40.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.37% | 24.32% | 26.54% | 31.02% | 40.16% |
| Cost of Revenue | 32.72% | -61.49% | -64.61% | -72.80% | -89.58% |
| Gross Profit | 23.98% | 157.49% | 156.90% | 174.65% | 231.23% |
| SG&A Expenses | 7.81% | -6.21% | 7.96% | 14.51% | 14.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2,112.37% | 12,914.29% | 12,914.29% | 12,914.29% | 12,914.29% |
| Total Operating Expenses | 16.98% | 17.14% | 29.72% | 35.28% | 33.35% |
| Operating Income | 13.44% | 6.15% | -43.28% | -53.60% | -11.12% |
| Income Before Tax | 13.06% | -5.94% | -29.63% | -67.98% | -38.74% |
| Income Tax Expenses | 66.98% | -137.17% | -125.31% | -139.93% | -149.33% |
| Earnings from Continuing Operations | 7.60% | 31.62% | 12.02% | -13.62% | -0.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.60% | 31.62% | 12.02% | -13.62% | -0.08% |
| EBIT | 13.44% | 6.15% | -43.28% | -53.60% | -11.12% |
| EBITDA | 14.61% | 6.07% | -49.94% | -66.27% | -19.85% |
| EPS Basic | 9.74% | 33.70% | 14.51% | -9.36% | 5.95% |
| Normalized Basic EPS | 21.13% | -6.44% | -31.16% | -66.99% | -32.06% |
| EPS Diluted | 9.38% | 33.34% | 15.42% | -7.99% | 7.04% |
| Normalized Diluted EPS | 20.71% | -6.92% | -29.78% | -64.96% | -30.72% |
| Average Basic Shares Outstanding | 2.26% | 2.79% | 3.47% | 5.39% | 6.96% |
| Average Diluted Shares Outstanding | 1.08% | 1.59% | 3.69% | 5.57% | 7.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
